JIANGSU HENGRUI MEDICINE CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 41.68 CNY | -1.58% |
|
-5.47% | -7.85% |
| Sales 2024 * | 26.55B 3.67B | Sales 2025 * | 30.3B 4.19B | Capitalization | 265B 36.61B |
|---|---|---|---|---|---|
| Net income 2024 * | 5.42B 749M | Net income 2025 * | 6.59B 910M | EV / Sales 2024 * | 9.12 x |
| Net cash position 2024 * | 23.01B 3.18B | Net cash position 2025 * | 27.53B 3.8B | EV / Sales 2025 * | 7.84 x |
| P/E ratio 2024 * |
47.7
x | P/E ratio 2025 * |
39.6
x | Employees | 19,611 |
| Yield 2024 * |
0.48% | Yield 2025 * |
0.55% | Free-Float | 51.08% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | -1.58% | ||
| 1 week | -5.47% | ||
| Current month | -9.33% | ||
| 1 month | -9.33% | ||
| 3 months | +0.65% | ||
| 6 months | -3.99% | ||
| Current year | -7.85% |
1 week
41.22
45.50
1 month
41.2246.86
Current year
35.5149.15
1 year
35.5150.50
3 years
27.0075.46
5 years
27.0097.39
10 years
6.9197.39
| Managers | Title | Age | Since |
|---|---|---|---|
Hong Bin Dai
CEO | Chief Executive Officer | 48 | 00-06-30 |
Jian Jun Liu
DFI | Director of Finance/CFO | 47 | 21-11-18 |
Yu Xu
CMP | Compliance Officer | 32 | 21-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jie Ping Sun
BRD | Director/Board Member | 54 | 97-12-31 |
Hong Bin Dai
CEO | Chief Executive Officer | 48 | 00-06-30 |
Piao Yang Sun
CHM | Chairman | 65 | 03-02-28 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 4.18% | 2 M€ | -20.87% | - | |
| 3.73% | 2 M€ | -14.14% | ||
| 1.74% | 1 M€ | -9.86% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 41.68 | -1.58% | 38,425,460 |
| 24-04-18 | 42.35 | -4.60% | 59,016,770 |
| 24-04-17 | 44.39 | +0.29% | 23,275,600 |
| 24-04-16 | 44.26 | -0.67% | 23,385,720 |
| 24-04-15 | 44.56 | +1.07% | 22,027,760 |
End-of-day quote Shanghai S.E., April 18, 2024
More quotes
Jiangsu Hengrui Medicine Co., Ltd. specializes in the research, development, manufacture and marketing of pharmaceutical products. The activity is organized primarily around 5 families of products:
- anti-tumor drugs (No. 1 Chinese);
- Anesthetic drugs;
- contrast agents: used in medical imaging;
- anti-inflammatory drugs;
- drugs for the treatment of cardiovascular diseases.
Sector
Pharmaceuticals
Calendar
2024-05-15
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
41.68
CNY
Average target price
57.89
CNY
Spread / Average Target
+38.88%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -7.85% | 37.2B | |
| +24.60% | 672B | |
| +24.08% | 550B | |
| -5.63% | 351B | |
| +15.37% | 317B | |
| +7.38% | 292B | |
| +3.26% | 211B | |
| +0.78% | 203B | |
| -9.69% | 144B | |
| -6.63% | 141B |
- Stock Market
- Equities
- 600276 Stock
